SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
APGE

Apogee Therapeutics, Inc. (NASDAQ:APGE)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$135.07+$0.00 (+0.00%)
 
Market cap
$8.40B
Insider Score
Health Score
Analyst consensus
Listed since
Jul 14, 2023
Market Cap$8.40B+239.2%
Revenue (ttm)$0
Net Income-$294.37M-23.9%
EPS-$4.34-4.3%
Shares Out62.20M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume0
Open$135.07
Previous Close$135.07
Day's Range$135.07 - $135.07
52-Week Range$35.39 - $135.09
Beta0.34
AnalystsHold
Price Target$129.91(-3.82%)
Earnings Daten/a
No price history available.

About APGE

Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.

Address
Building 17, Waltham, MA, 02453, US
Market Cap
8.40 billion
Employees
261
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$22.79M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

When insiders bought and sold

1 year · open-market trades only
Closing Price Purchase Sale
$57.16$99.50$142DecFebAprJunAug
Financial Health Score
Fair
From APGE’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars
1 Day
+0.00%
5 Days
+0.00%
1 Month
+0.00%
6 Months
+60.78%
1 Year
+239.20%

$APGE stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in APGE holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by APGE's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

APGE Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New APGE patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to APGE from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in APGE

ARBAltShares Merger Arbitrage ETF$2.49M
EVNTAltShares Event-Driven ETF$188.30K
VETSPacer Military Times Best Employers ETF$76.88K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from APGE’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
50
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
20
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

ARBAltShares Merger Arbitrage ETF2.45%
EVNTAltShares Event-Driven ETF1.45%

Weight is the stock’s share of each fund’s holdings.